^
    Back
    Association details:
    Biomarker:ASF1B overexpression
    Cancer:Hepatocellular Cancer
    Drug Class:PD-L1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Front Genet
    Title:

    ASF1B is a Promising Prognostic Biomarker and Correlates With Immunotherapy Efficacy in Hepatocellular Carcinoma

    Published date:
    03/10/2022
    Excerpt:
    The Imvigor210 cohort was retrieved to assess the ability of ASF1B to predict immunotherapy efficacy….Patients who received anti-PD-L1 immunotherapy with high ASF1B expression had a higher objective response.
    DOI:
    https://doi.org/10.3389/fgene.2022.842351
    Trial ID:
    NCT02108652